LinkedIn · Jul 2026
Company post noting workshop sponsorship and that co-founder/CSO Ashwin Jainarayanan presented the work, with co-founder Michael Dustin thanked as an organizer.
Reprogramming Immunity for Target-Specific Medicines
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Granza Bio is a San Francisco-based biotechnology startup building programmable therapeutic delivery shells around immune-system “attack particles” (supramolecular attack particles/SMAPs) for cancer and other hard-to-treat diseases. Public company materials and press describe the company as founded in 2024, though LinkedIn also lists 2023.
Primary product
Precision delivery shell platform for immune “attack particles” / therapeutic cargo delivery
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Drug discovery / oncology therapeutics
Offices
San Francisco, California, United States
United Kingdom
Singapore
Business model
Biotech therapeutic platform
Partnership and licensing
Funding
People & investors
Leadership
Founder & CEO
Founder & CSO
Senior Director, Head of Non-Viral Delivery
Co-founder / scientific advisor
Work & culture
Highly scientific and research-driven, with an Oxford-rooted founding team, active conference/workshop participation, and frequent sharing of preprints and academic milestones.
Product & market
Pricing
Not publicly disclosed; partnership/licensing inquiries are public.
Differentiators
- —Uses immune-system-derived attack particles/SMAPs as the biological core of the platform
- —Aims to direct therapeutic cargo to specific tissues with precision delivery shells
- —Positions the platform for localized killing while minimizing damage to healthy tissue
- —Claims potential applicability across cancer, autoimmunity, and infections
- —Scientific foundation comes from University of Oxford research
Technology
Precision delivery shells
Supramolecular attack particles (SMAPs)
Therapeutic cargo delivery
Immune-cell derived cytotoxic payloads
Competitors
Jazz Pharmaceuticals
Sana Biotechnology
Senti Bio
Aronora
Macomics
Meditope Biosciences
Mestag Therapeutics
Centrose
Scale & contact
Estimated revenue
$100K-$5.0M (Owler estimate)
Estimated monthly visits
266
Latest news
BioEscalator · Jul 2026
BioEscalator article says Granza Bio won Best Pitch and Best Scientific Explanation at the 2026 pitch battle.
PR Newswire · Jul 2024
Official company press release announcing the oversubscribed $7.14M seed and naming the broader investor syndicate and founders.
Endpoints · Jul 2024
Short funding note confirming the $7M seed and that the company is using the capital to pursue its delivery platform.
TechCrunch · Jul 2024
Reports the $7.14M seed round led by Felicis and Refactor, with Y Combinator participation, and explains the attack-particles delivery concept.
Jobs and careers at Granza Bio
0 jobs at Granza Bio
No open positions
Check back later for new openings